Authors

Latest:

Dr. Moyers on Real-World Data With Adjuvant Immunotherapy in Melanoma

Justin Moyers, MD, discusses real-world data and sociodemographic factors from an early analysis of the National Cancer Database associated with the treatment of adjuvant immunotherapy in stage III melanoma.

Jimmy Hwang, MD

Latest:

Dr. Hwang on Considerations for Second-Line Treatment in Gastric/GEJ Cancer

Jimmy Hwang, MD, discusses considerations for second-line treatment in gastric/gastroesophageal junction cancer.

Anna Barata, PhD

Latest:

Dr. Barata on Patient-Reported Toxicities With Axi-Cel at 1-Year of Follow-Up

Anna Barata, PhD, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel) in patients 1-year post-infusion.

Sakti Chakrabarti, MD

Latest:

Drawing Actionable Information From the Blood in Advanced Biliary Tract Cancer

A major barrier to routine genomic profiling of tumors in patients with biliary tract cancer is the lack of adequate tumor tissue in the biopsy samples; the analysis of circulating tumor DNA present in the plasma, is emerging as a promising alternative.

Bo Wang, MD

Latest:

Find the Job That’s Right for You

The American Society of Clinical Oncology projects significant shortages of practicing oncologists compared with patients with new cancer diagnoses and existing cancer by 2025.

Benjamin Margolis, MD, and Julia Fehniger, MD

Latest:

Deciding When to Defer Oncology Treatment

Oncologists are challenged to make a different determination when a new patient presents with advanced cancer.

Cyrus Khan, MD, West Penn Hospital

Latest:

Treating Patients Post CAR T Therapy

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Gina Mauro

Editorial Director,

Latest:

FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia

The FDA has extended the review period for the new drug application for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and severe thrombocytopenia with a baseline platelet count of 50 x 109/L.

Jerry Le Pow Spivak, MD

Latest:

Dr. Spivak on Diagnosing Essential Thrombocythemia

Jerry Le Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center

Latest:

Treatment Approaches for TP53-Mutated AML

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Anita Kumar, MD

Latest:

Dr. Kumar on the Future Directions With Pirtobrutinib in MCL

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

Jennifer Woyach, MD, Ohio State University

Latest:

Emerging Agents for R/R CLL

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Hans Wildiers, MD

Latest:

Dr. Wildiers on the Final Results of the AIPAC Trial in HR+/HER2- Metastatic Breast Cancer

Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Yoomi Lee, MD

Latest:

Dr. Lee on Selecting a Treatment Approach for Neuroendocrine Tumors

Yoomi Lee, MD, discusses her process for selecting a treatment approach for patients with neuroendocrine tumors.

Apar Ganti, MD, University of Nebraska Medical Center

Latest:

Recent Advances in Small-Cell Lung Cancer

Mitchell E. Horwitz, MD

Latest:

Dr. Horwitz on the Clinical Benefit of Omidubicel Transplant in Hematologic Malignancies

Mitchell E. Horwitz, MD, discusses the use of omidubicel versus standard myeloablative umbilical cord blood transplant in patients with hematologic malignancies.

Courtney Marabella

Senior Editor,

Latest:

Cleveland Clinic Launches Trial Examining Preventive Vaccine for TNBC

Cleveland Clinic has partnered with Anixa Biosciences, Inc. to open a phase 1 trial examining a vaccine aimed at preventing the development of triple-negative breast cancer.

Natalie S. Callander, MD, University of Wisconsin School of Medicine and Public Health

Latest:

Influencing Factors to Initially Targeting BCMA in MM

Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine

Latest:

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Pankit Vachhani, MD, University of Alabama at Birmingham Hospital

Latest:

Ruxolitinib for Myelofibrosis: Treatment Considerations

Pankit Vachhani, MD, explains how to properly treat myelofibrosis using ruxolitinib based on data provided by key clinical trials like COMFORT-I and COMFORT-II.